Table 3.
Cumulative fraction of response (CFRs) of quasi-optimal (namely fCtrough/MIC or fCss/MIC ratio ≥ 1) and optimal (namely fCtrough/MIC or fCss/MIC ratio ≥ 4) PK/PD targets achievable with the tested dosages of ceftobiprole against the EUCAST MIC distribution of MRSA and MRSE in the different classes of renal function.
| Ceftobiprole Dosages and Classes of eGFR |
MRSA | MRSE | ||
|---|---|---|---|---|
| Quasi-Optimal PK/PD Target | Optimal PK/PD Target | Quasi-Optimal PK/PD Target | Optimal PK/PD Target | |
| eGFR < 30 mL/min/1.73 m2 | ||||
| 250 q12h EI | 95.9 | 58.2 | 88.1 | 52.9 |
| 250 q12h CI | 99.7 | 79.1 | 91.3 | 73.9 |
| 250 q8h EI * | 98.8 | 80.7 | 90.7 | 75.2 |
| 250 q8h CI * | 100 | 91.4 | 91.4 | 85.4 |
| eGFR 30–50 mL/min/1.73 m2 | ||||
| 500 q12h EI | 98.6 | 78.4 | 90.4 | 72.9 |
| 500 q12h CI | 99.9 | 94.5 | 91.4 | 88.1 |
| 500 q8h EI * | 99.7 | 92.6 | 91.2 | 85.8 |
| 500 q8h CI * | 100 | 98.4 | 91.4 | 90.7 |
| eGFR 51–80 mL/min/1.73 m2 | ||||
| 500 q8h EI | 99.5 | 83.2 | 91.1 | 77.1 |
| 500 q8h CI | 100 | 96.8 | 91.4 | 89.7 |
| 500 q6h EI * | 99.4 | 93.4 | 91.3 | 86.6 |
| 500 q6h CI * | 100 | 98.9 | 91.4 | 91.0 |
| eGFR 81–130 mL/min/1.73 m2 | ||||
| 500 q8h EI | 97.2 | 66.0 | 89.4 | 60.8 |
| 500 q8h CI | 100 | 90.5 | 91.4 | 84.8 |
| 500 q6h EI * | 99.4 | 83.5 | 91.0 | 77.7 |
| 500 q6h CI * | 100 | 96.5 | 91.4 | 90.0 |
| eGFR > 130 mL/min/1.73 m2 | ||||
| 500 q8h EI | 75.2 | 22.2 | 69.3 | 18.3 |
| 500 q8h CI | 99.2 | 66.7 | 91.1 | 61.3 |
| 500 q6h EI * | 89.2 | 41.1 | 82.3 | 36.2 |
| 500 q6h CI * | 99.8 | 82.3 | 91.2 | 77.1 |
| 500 q4h EI * | 98.4 | 72.2 | 90.3 | 66.7 |
| 500 q4h CI * | 100 | 92.5 | 91.4 | 86.4 |
* Intensified dosages tested in different classes of eGFR. CI, 24 h-continuous infusion; EI, 2 h-extended infusion.